| Literature DB >> 23414245 |
Klaus W Neuhaus1, Jeffery L Milleman, Kimberly R Milleman, Kimberly A Mongiello, Thomas C Simonton, Courtney E Clark, Howard M Proskin, Rainer Seemann.
Abstract
AIMS: The aim of this single-site, randomized, controlled, double-blind, 3-arm parallel study was to determine the effectiveness of a prophylaxis paste containing 15% calcium sodium phosphosilicate (CSPS; NovaMin(®) ) with and without fluoride in reducing dentine hypersensitivity immediately after a single application and 28 days following dental scaling and root planing. MATERIALS &Entities:
Mesh:
Substances:
Year: 2013 PMID: 23414245 PMCID: PMC3675645 DOI: 10.1111/jcpe.12057
Source DB: PubMed Journal: J Clin Periodontol ISSN: 0303-6979 Impact factor: 8.728
Prophylaxis pastes product details
| Group | Product | Ingredients |
|---|---|---|
| Test-A | NUPRO® Sensodyne® Prophylaxis Paste, with NovaMin® without fluoride (polish, spearmint) Lot # 11090809 | Pumice and glycerin base, 15% NovaMin |
| Test-B | NUPRO® Sensodyne® Prophylaxis Paste, with NovaMin® with fluoride (polish, spearmint) Lot # 11090908 | Pumice and glycerin base, 15% NovaMin 2.7% NaF |
| Control | NUPRO® Classic without fluoride (medium, mint) Lot # 10081802 | Pumice and glycerin base |
Figure 1Summary flow-chart of study design
Tactile sensitivity scores; between-treatment p-values for the baseline visit are calculated using an anova model that includes fixed factor treatment
| Assessment/Treatment | Tactile sensitivity | Change from baseline | Between-Treatment | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Median | Min. | Max. | Mean | SD | Median | Min. | Max. | vs. Test-A | vs. Test-B | vs. Control | |||||
| Baseline | Test-A | 49 | 10.41 | 1.38 | 10.00 | 10.0 | 15.0 | 0 | – | – | – | – | – | – | – | n.s. | n.s. |
| Test-B | 52 | 10.38 | 1.35 | 10.00 | 10.0 | 15.0 | 0 | – | – | – | – | – | – | n.s. | – | n.s. | |
| Control | 50 | 10.60 | 1.64 | 10.00 | 10.0 | 15.0 | 0 | – | – | – | – | – | – | n.s. | n.s. | – | |
| Post-Prophy | Test-A | 49 | 20.87 | 12.64 | 15.00 | 10.0 | 55.0 | 49 | 10.46 | 12.58 | 5.00 | 0.0 | 45.0 | <0.0001 | – | n.s. | <.0001 |
| Test-B | 52 | 22.74 | 12.99 | 20.00 | 10.0 | 55.0 | 52 | 12.36 | 12.91 | 10.00 | −5.0 | 45.0 | <0.0001 | n.s. | – | <.0001 | |
| Control | 50 | 11.20 | 3.12 | 10.00 | 10.0 | 25.0 | 50 | 0.60 | 3.45 | 0.00 | −5.0 | 15.0 | n.s. | <0.0001 | <.0001 | – | |
| Day 28 | Test-A | 49 | 21.48 | 11.86 | 20.00 | 10.0 | 55.0 | 49 | 11.07 | 11.90 | 10.00 | 0.0 | 45.0 | <0.0001 | – | n.s. | <.0001 |
| Test-B | 52 | 20.58 | 11.32 | 17.50 | 10.0 | 55.0 | 52 | 10.19 | 11.37 | 5.00 | −5.0 | 45.0 | <0.0001 | n.s. | – | <.0001 | |
| Control | 48 | 11.77 | 5.95 | 10.00 | 10.0 | 37.5 | 48 | 1.15 | 5.88 | 0.00 | −5.0 | 27.5 | n.s. | <0.0001 | <.0001 | – | |
Between-treatment p-values for the subsequent visits are calculated using an ancova model that includes fixed factor treatment, and the baseline tactile sensitivity score as a covariate.
n.s. = non-significant.
Summary of tooth-wise tactile sensitivity scores. Number of subjects exhibiting each non-missing score; transition baseline to Post-Prophy and Day 28
| Baseline score | Post-Prophy score | Day 28 score | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 | 20 | 30 | 40 | 50 | > 55 | 10 | 20 | 30 | 40 | 50 | > 55 | ||
| Test-A | 10 | 53 | 14 | 9 | 8 | 3 | 7 | 44 | 18 | 19 | 5 | 1 | 7 |
| 20 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| 30 | |||||||||||||
| 40 | |||||||||||||
| 50 | |||||||||||||
| > 55 | |||||||||||||
| Test-B | 10 | 43 | 22 | 15 | 9 | 4 | 7 | 49 | 22 | 16 | 6 | 1 | 6 |
| 20 | 1 | 3 | 1 | 1 | 1 | 1 | |||||||
| 30 | |||||||||||||
| 40 | |||||||||||||
| 50 | |||||||||||||
| > 55 | |||||||||||||
| Control | 10 | 86 | 6 | 2 | 83 | 4 | 1 | 2 | |||||
| 20 | 4 | 2 | 5 | 1 | |||||||||
| 30 | |||||||||||||
| 40 | |||||||||||||
| 50 | |||||||||||||
| > 55 | |||||||||||||
Within each treatment, cells above the diagonal represent sensitivity reductions between the time-points.
Between-treatment p-values for the baseline visit are calculated using an anova model that includes fixed factor treatment
| Assessment/Treatment | Air blast sensitivity | Change from baseline | Between-Treatment | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Median | Min. | Max. | Mean | SD | Median | Min. | Max. | vs. Test-A | vs. Test-B | vs. Control | |||||
| Baseline | Test-A | 49 | 1.93 | 0.59 | 2.00 | 1.0 | 3.0 | 0 | – | – | – | – | – | – | – | n.s. | n.s. |
| Test-B | 52 | 1.93 | 0.59 | 2.00 | 1.0 | 3.0 | 0 | – | – | – | – | – | – | n.s. | – | n.s. | |
| Control | 50 | 1.97 | 0.63 | 2.00 | 1.0 | 3.0 | 0 | – | – | – | – | – | – | n.s. | n.s. | – | |
| Post-Prophy | Test-A | 49 | 1.07 | 0.64 | 1.00 | 0.0 | 3.0 | 49 | −0.86 | 0.62 | −1.00 | −2.5 | 0.5 | <0.0001 | – | n.s. | <0.0001 |
| Test-B | 52 | 1.07 | 0.62 | 1.00 | 0.0 | 2.5 | 52 | −0.87 | 0.71 | −1.00 | −2.5 | 0.0 | <0.0001 | n.s. | – | <0.0001 | |
| Control | 50 | 1.97 | 0.70 | 2.00 | 0.0 | 3.0 | 50 | 0.00 | 0.35 | 0.00 | −1.0 | 1.0 | n.s. | <0.0001 | <0.0001 | – | |
| Day 28 | Test-A | 49 | 0.98 | 0.62 | 1.00 | 0.0 | 3.0 | 49 | −0.95 | 0.66 | −1.00 | −2.5 | 0.5 | <0.0001 | – | n.s. | <0.0001 |
| Test-B | 52 | 0.99 | 0.55 | 1.00 | 0.0 | 2.5 | 52 | −0.94 | 0.68 | −1.00 | −2.5 | 0.5 | <0.0001 | n.s. | – | <0.0001 | |
| Control | 48 | 2.03 | 0.67 | 2.00 | 0.5 | 3.0 | 48 | 0.03 | 0.47 | 0.00 | −1.0 | 1.0 | n.s. | <0.0001 | <0.0001 | – | |
Between-treatment p-values for the subsequent visits are calculated using an ancova model that includes fixed factor treatment, and the baseline air blast sensitivity score as a covariate.
n.s. = non-significant.
Summary of tooth-wise Schiff Air Blast Sensitivity Scores. Number of subjects exhibiting each non-missing score; transition. Baseline to Post-Prophy and Day 28
| Baseline score | Post-Prophy score | Day 28 score | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | ||
| Test-A | 0 | ||||||||
| 1 | 9 | 16 | 2 | 10 | 16 | 1 | |||
| 2 | 12 | 28 | 11 | 12 | 32 | 7 | |||
| 3 | 2 | 4 | 11 | 3 | 2 | 7 | 8 | 3 | |
| Test-B | 0 | ||||||||
| 1 | 9 | 19 | 11 | 15 | 2 | ||||
| 2 | 10 | 27 | 18 | 12 | 27 | 16 | |||
| 3 | 2 | 11 | 6 | 2 | 4 | 10 | 6 | 1 | |
| Control | 0 | ||||||||
| 1 | 5 | 13 | 8 | 2 | 15 | 6 | |||
| 2 | 2 | 1 | 43 | 5 | 1 | 4 | 33 | 12 | |
| 3 | 3 | 20 | 7 | 16 | |||||
Within each treatment, cells below the diagonal represent sensitivity reductions between the time-points.
Summary of self-assessed sensitivity (questionnaire); between-treatment p-values for the baseline visit are calculated using an anova model that includes fixed factor treatment
| Assessment/Treatment | Subject-Assessed sensitivity | Change from baseline | Between-Treatment | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Mean | S.D. | Median | Min. | Max. | n | Mean | S.D. | Median | Min. | Max. | vs. Test-A | vs. Test-B | vs. Control | |||
| Baseline | Test-A | 49 | 0.90 | 0.82 | 1 | 0 | 3 | 0 | – | n.s. | n.s. | ||||||
| Test-B | 52 | 0.67 | 0.68 | 1 | 0 | 2 | 0 | n.s. | – | n.s. | |||||||
| Control | 50 | 0.86 | 0.76 | 1 | 0 | 2 | 0 | n.s. | n.s. | – | |||||||
| Post-Scaling/Root Planing | Test-A | 49 | 1.31 | 0.85 | 1 | 0 | 3 | 49 | 0.41 | 0.93 | 0 | −2 | 3 | 0.0036 | – | n.s. | n.s. |
| Test-B | 52 | 1.19 | 0.72 | 1 | 0 | 3 | 52 | 0.52 | 0.67 | 1 | −1 | 2 | 0.0002 | n.s. | – | n.s. | |
| Control | 50 | 1.36 | 0.75 | 1 | 0 | 3 | 50 | 0.50 | 0.89 | 0 | −2 | 3 | <0.0001 | n.s. | n.s. | – | |
| Post-Prophy | Test-A | 49 | 1.14 | 0.76 | 1 | 0 | 3 | 49 | 0.24 | 0.90 | 0 | −2 | 3 | n.s. | – | n.s. | n.s. |
| Test-B | 52 | 0.96 | 0.74 | 1 | 0 | 2 | 52 | 0.29 | 0.78 | 0 | −2 | 2 | 0.0203 | n.s. | – | n.s. | |
| Control | 50 | 1.20 | 0.90 | 1 | 0 | 3 | 50 | 0.34 | 1.00 | 0 | −2 | 2 | 0.0098 | n.s. | n.s. | – | |
| Day 28 | Test-A | 49 | 0.47 | 0.62 | 0 | 0 | 3 | 49 | −0.43 | 0.82 | 0 | −3 | 1 | 0.0006 | – | n.s. | 0.0010 |
| Test-B | 52 | 0.52 | 0.64 | 0 | 0 | 2 | 52 | −0.15 | 0.80 | 0 | −2 | 2 | n.s. | n.s. | – | 0.0236 | |
| Control | 48 | 0.88 | 0.79 | 1 | 0 | 3 | 48 | 0.02 | 0.70 | 0 | −2 | 3 | n.s. | 0.0010 | 0.0236 | – | |
Between-treatment p-values for the subsequent visits are calculated using an ancova model that includes fixed factor treatment, and the baseline Subject-Assessed sensitivity score as a covariate.
n.s. = non-significant.